Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07778524) titled 'Alpelisib Challenge Test (ACT)' on Aug. 18.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: Columbia University
Condition:
Insulin Resistance
Type 2 Diabetes
Obesity & Overweight
Healthy Adult Participants
Intervention:
Drug: Alpelisib 300 mg
Diagnostic Test: Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 1, 2026
Target Sample Size: 15
Count...